In a significant leap forward for interventional cardiology, Philips has officially unveiled SmartIQ, an advanced artificial intelligence (AI)-powered software suite designed to fundamentally alter the landscape of coronary imaging. By tackling the long-standing clinical dilemma—the inverse relationship between high-resolution image quality and patient radiation exposure—Philips is positioning its new technology as the next frontier in the Azurion image-guided therapy platform.
As the medical community convenes at the 2026 EuroPCR conference in Paris (May 19–22), SmartIQ is taking center stage as a solution that promises to redefine safety protocols without compromising the diagnostic precision required for complex cardiac procedures.
The Core Challenge: Balancing Clarity and Safety
For decades, clinicians performing coronary angiography and percutaneous coronary interventions (PCI) have operated under a restrictive paradigm. To achieve the sharp, high-contrast images necessary to navigate the intricate vasculature of the heart, traditional systems required higher X-ray dosages. Conversely, lowering radiation doses often resulted in image "noise" or graininess, which could hinder a surgeon’s ability to visualize thin wires or stents accurately.
Philips’ new SmartIQ algorithm directly confronts this "fundamental trade-off." By integrating sophisticated AI-based noise reduction and image enhancement, the software allows the Azurion system to maintain crystalline image quality even when the X-ray tube output is dialed down significantly.
A Chronological Evolution of Imaging Technology
The journey to SmartIQ is not an overnight breakthrough but the latest chapter in a broader strategy to digitize and optimize image-guided therapy.
- The ClarityIQ Era: Before SmartIQ, Philips established a benchmark with its ClarityIQ technology. Built into the Azurion platform, ClarityIQ utilized real-time image processing to lower radiation doses while maintaining diagnostic-grade visualization. It became a staple in cath labs globally for its ability to reduce radiation exposure for both patients and medical staff.
- The Development Phase: Recognizing that further reductions were possible through machine learning, Philips engineers spent years developing neural networks capable of recognizing and suppressing noise patterns specific to cardiac motion.
- May 12, 2026: Philips published the results of a blinded clinical pilot study in the Journal of the Society for Cardiovascular Angiography & Interventions, providing the first peer-reviewed evidence of the technology’s efficacy.
- May 19–22, 2026: Official public debut at the EuroPCR conference in Paris, signaling the technology’s transition from research and development to clinical application.
Supporting Data: Why SmartIQ Changes the Math
The clinical evidence supporting SmartIQ suggests that the industry is moving toward an era of "ultra-low dose" procedures.
The 50% Threshold
According to technical specifications provided by Philips, the ultra-low dose protocol enabled by SmartIQ utilizes over 50% less X-ray radiation compared to the lowest dose settings previously achievable with ClarityIQ. This represents a massive reduction in cumulative lifetime radiation exposure for patients undergoing repeat procedures and for the cardiologists who spend thousands of hours under the fluoroscope annually.
Clinical Pilot Results
In the blinded pilot study published in the Journal of the Society for Cardiovascular Angiography & Interventions, clinicians were asked to evaluate images produced by both ClarityIQ and the new SmartIQ system. The results were compelling:
- Preference: SmartIQ was preferred in the vast majority of blinded comparisons.
- Quality: Despite the lower radiation input, SmartIQ-processed images were scored higher in terms of clinical utility and diagnostic clarity.
- Efficiency: The trial confirmed that the system could maintain these superior quality metrics while simultaneously keeping contrast media doses—which can be nephrotoxic—stable or lower.
The RADIQAL Trial: Real-World Validation
Beyond the pilot study, the ongoing RADIQAL trial (NCT06944509) serves as the ultimate litmus test. Currently boasting a 60% enrollment rate, this study is designed to generate robust, real-world evidence across diverse clinical environments. By monitoring how the software performs in high-volume, real-world cardiac catheterization labs, Philips is ensuring that the laboratory results translate seamlessly into the high-pressure environment of emergency and elective surgery.
Official Responses and Strategic Vision
The launch of SmartIQ reflects a shift in Philips’ broader business strategy: moving from hardware-centric sales to software-defined medical outcomes.
Mark Stoffels, Business Leader for Image-Guided Therapy Systems at Philips, emphasized the paradigm shift during the product launch:
"For too long, clinicians have had to choose between image quality and radiation dose during coronary procedures. With our breakthrough SmartIQ technology, we believe that trade-off no longer has to define coronary imaging. This is not an incremental step forward—it represents one of Philips’ boldest advances yet in helping clinicians see what they need while aiming to further reduce exposure for patients and clinical teams."
By framing the product not as an "incremental update" but as a "bold advance," Philips is signaling to the market that it intends to capture a larger share of the interventional space by addressing the occupational health concerns of cardiologists—a demographic increasingly focused on the long-term effects of chronic radiation exposure.
Implications for the Future of Healthcare
The introduction of SmartIQ arrives at a pivotal moment in the medical technology industry, where AI integration is no longer a luxury but a requirement for competitiveness.
The Economic Impact of AI in Imaging
According to recent analysis by GlobalData, the medical AI market is experiencing explosive growth. Valued at $11.9 billion in 2024, the sector is projected to hit $57.4 billion by 2029. SmartIQ is a prime example of how AI is being monetized within the high-end medical device sector: by providing software-based enhancements that extend the lifecycle and capabilities of existing hardware platforms like the Azurion.
Occupational Health and Safety
The most immediate implication of SmartIQ is the improvement in occupational safety for interventional cardiologists, nurses, and technicians. Chronic exposure to ionizing radiation has long been a source of anxiety for cath lab staff. By cutting doses by half, hospitals can significantly mitigate long-term health risks for their staff, potentially reducing insurance premiums and improving recruitment and retention in high-stress specialties.
Regulatory Landscape
While SmartIQ has secured the European CE mark, indicating it is ready for deployment in European markets, its absence in the US market highlights the current regulatory hurdle. As the company seeks FDA clearance, the ongoing data from the RADIQAL trial will likely serve as the foundational evidence package for US regulatory submission.
Implications for Patient Outcomes
Ultimately, the primary beneficiary is the patient. Lower radiation doses are particularly critical for pediatric cardiac patients, patients with chronic conditions requiring frequent surveillance, and those who are elderly or frail. By making "ultra-low dose" the new standard, Philips is democratizing high-quality care that minimizes collateral harm.
Conclusion: A New Standard for the Cath Lab
As the medical industry continues to digest the implications of AI, tools like SmartIQ are transforming from "experimental" to "essential." By solving the conflict between image fidelity and radiation safety, Philips has established a new benchmark for what is possible in the operating room.
As the RADIQAL trial moves toward completion and the technology begins its rollout across European hospitals, the global cardiology community will be watching closely. If the promise of SmartIQ holds true in the diverse, messy, and fast-paced reality of clinical medicine, the "fundamental trade-off" that has defined the last fifty years of coronary imaging may soon be a thing of the past. For now, the EuroPCR conference marks the beginning of a new, safer, and clearer era for interventional cardiology.
About the Author
